Hong Kong stock movement: REMEGEN rises 14.09%, with clear capital flow, market sentiment triggers volatility attention

Hong Kong Stock Movement REMEGEN rose 14.09%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks Ranked High in Industry Transaction Volume Kangfang Biotech rose 6.76%. Based on recent news, On March 30, Kangfang Biotech's two globally innovative tumor immune dual antibodies were included in the national medical insurance catalog for the first time, driving the stock price up. The company's revenue is expected to grow by 43.9% year-on-year in 2025, reaching RMB 3.056 billion. Source: Zhitong Finance On March 30, Kangfang Biotech was considered one of the securities with the highest short-term speculative value, attracting investor attention. Source: Economic News On April 1, Kangfang Biotech recorded revenue growth in 2025, but losses widened, and the market holds an optimistic view on its future development. Source: KGI Asia's pharmaceutical industry has performed strongly recently, with significant capital inflow. Sihuan Pharmaceutical rose 11.40%. Based on recent key news: On April 1, Sihuan Pharmaceutical announced the physical distribution of all shares of Mandi International, with the stock price opening high and rising. This move is seen as a special return to shareholders, pushing the stock price up to HKD 24.96, with a transaction volume of HKD 922 million. Source: Zhitong Finance On March 30, Sihuan Pharmaceutical released its full-year performance for 2025, with revenue growth of 94.3% and net profit growth of 305.8%. Strong financial performance boosted market confidence, driving the stock price up. Source: Zhitong Finance On March 31, the biopharmaceutical sector was listed as a new emerging pillar industry by the state, and policy support enhanced market expectations for Sihuan Pharmaceutical's innovation potential. The company's investment in R&D and innovation has gained international recognition, further driving the stock price up. Source: Zhitong Finance, policy support for the biopharmaceutical industry enhances market confidence. Innovent Biologics rose 6.77%. Based on recent news, On March 30, Innovent Biologics announced that the Phase Ib clinical study of Ma Shidu Peptide in the Chinese adolescent obesity population reached its primary endpoint, showing significant blood sugar reduction and weight loss effects. This news boosted market confidence, driving the stock price up. On March 30, Innovent Biologics announced its fiscal year 2025 performance, recording a net profit of RMB 834 million for the first time, with total revenue reaching RMB 13 billion, a year-on-year increase of 38%. Strong financial performance further enhanced investor confidence. On March 30, Innovent Biologics granted stock options and restricted shares to grantees under the stock plan, with an exercise price of HKD 86.1 per share. This incentive measure was interpreted by the market as the company's confidence in future development, driving the stock price up. The innovative drug industry is highly competitive, with significant pressure from medical insurance payments. Stocks Ranked High in Industry Market Capitalization BeiGene rose 7.58%. Based on recent key news: On March 30, the National Medical Products Administration announced that the total value of innovative drug licensing transactions in the first quarter of 2026 exceeded USD 60 billion, with BeiGene participating in multiple transactions, driving the stock price up Source: National Medical Products Administration On April 1st, BeiGene recorded large transactions in pre-market trading, with a transaction price 0.84% higher than the previous closing price, indicating positive market sentiment towards its stock. Source: Economic News Agency The innovative drug sector has significant development potential, with noticeable capital inflows